Rising tariffs, inflation, and geopolitical shifts are disrupting diabetes technology manufacturing and pricing, analysts say.
Global diabetes technology supply chains face growing strain from tariffs, inflation, and geopolitical shifts, reshaping production and pricing through 2026. Analysts warn these pressures may alter where devices are manufactured and which products reach patients, impacting costs and availability.